GlassScriptPhysician profile
Timothy A Naumann
NPI 1992188379
$12,701.89
in general payments reported to CMS, 2019-2025
24 companies · $2,596 in 2025
The $2,596 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $454 · 2022: $317 · 2023: $4,291 · 2024: $5,044 · 2025: $2,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,750 · Food and Beverage: $3,980 · Travel and Lodging: $1,154 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,750.00 |
| Food and Beverage | $3,980.09 |
| Travel and Lodging | $1,154.00 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,304.61 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,470.28 | 2023-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $534.63 | 2022-2025 | Caplyta |
| Alkermes, INC. | $429.77 | 2021-2025 | Vivitrol, Vivitrol |
| Supernus Pharmaceuticals, INC. | $335.85 | 2022-2024 | Qelbree, Xyosted, Qelbree |
| Otsuka America Pharmaceutical, INC. | $279.32 | 2021-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $265.03 | 2023-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $185.86 | 2024-2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $136.74 | 2024-2025 | Auvelity |
| Indivior INC. | $114.48 | 2021-2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $103.09 | 2023-2025 | Quviviq, Quviviq |
| Sunovion Pharmaceuticals INC. | $93.48 | 2021-2022 | |
| Lundbeck LLC | $88.04 | 2022-2025 | Rexulti |
| Braeburn INC. | $73.73 | 2025 | Brixadi |
| Corium, LLC | $70.49 | 2023-2025 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $41.63 | 2023-2025 | Dyanavel Xr |
| Halozyme INC | $34.39 | 2023 | |
| Neurocrine Biosciences, INC. | $32.95 | 2023-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $20.41 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $20.18 | 2025 | Jornay Pm |
| Gilead Sciences, INC. | $19.08 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $17.80 | 2025 | Uzedy |
| Biodelivery Sciences International, INC. | $16.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Naumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.